Microbot Medical Inc. (MBOT)
| Market Cap | 49.97M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -9.17M |
| Shares Out | 7.12M |
| EPS (ttm) | -1.29 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $7.03 |
| Previous Close | $6.95 |
| Change ($) | 0.08 |
| Change (%) | 1.15% |
| Day's Open | 7.00 |
| Day's Range | 6.94 - 7.29 |
| Day's Volume | 97,737 |
| 52-Week Range | 6.03 - 12.20 |
Scientific Advisory Board Expanded with Additions of Global Medical Pioneers and Distinguished Thought Leaders Scientific Advisory Board Expanded with Additions of Global Medical Pioneers and Distinguis...
Results Validate Findings of Initial Study; End Points Achieved with No Intraoperative Adverse Events
HINGHAM, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that Harel Gadot, CEO, President and Chief Executive Officer, will be presenting virtually at two upcomi...
HINGHAM, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced that it has received patents in multiple jurisdictions, further demonstrating the Company's continued exe...
Webcast to be Held on Thursday November 12 th at 2:00pm ET
HINGHAM, Mass., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent ap...
Webinar to be Held on Wednesday August 26th at 11am ET Webinar to be Held on Wednesday August 26th at 11am ET
World’s First Fully Disposable Surgical Robot Achieved all Endpoints with No Intraoperative Adverse Events
Results to be shared on August 17th during Needham’s Virtual Med Tech & Diagnostics Conference Results to be shared on August 17th during Needham’s Virtual Med Tech & Diagnostics Conference
Vascular Interventions Executive Will Contribute Significantly to the Development and Commercialization of LIBERTY Robotic System Vascular Interventions Executive Will Contribute Significantly to the De...
Microbot: Miniature Medical Device Company Can Be Successful
Proven Track Record of Numerous M&A and Strategic Collaboration Transactions Proven Track Record of Numerous M&A and Strategic Collaboration Transactions
HINGHAM, Mass., March 03, 2020 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Microbot Medical Inc. (NASDAQ: MBOT), please note that in the first paragraph the appoin...
HINGHAM, Mass., March 03, 2020 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ: MBOT), announced the appointment of Eyal Morag, M.D., a leading radiologist, to Chief Medical Officer, effective immed...
As of late, it has definitely been a great time to be an investor Microbot Medical.
Multibagger stocks can make most of the bull run, courtesy of strong fundamentals and businesses that can multiply in a short span of time.
HINGHAM, Mass., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) has received an official communication from the European Patent Office (EPO) regarding its intention to grant Eur...
HINGHAM, Mass., Dec. 31, 2019 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT ) closed its previously announced registered direct offering of 900,901 shares of its common stock at a purchase...
HINGHAM, Mass., Dec. 30, 2019 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical te...
Microbot Medical Inc. shares slid 24% Friday, after the medical device company announced a $10 million registered direct offering priced at-the-market at $10.50, a discount to its closing price Thursda...
HINGHAM, Mass., Dec. 27, 2019 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical te...
HINGHAM, Mass., Dec. 27, 2019 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq:MBOT) closed its previously announced registered direct offering of 912,858 shares of its common stock at a purchase pri...
HINGHAM, Mass., Dec. 26, 2019 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical te...
Microbot Medical Inc. (NASDAQ: MBOT) shares made a massive gain on Tuesday after the company revealed its Liberty system, which would be the world’s first fully disposable robotic system for use in neur...
Microbot Medical to Unveil World’s First Fully Disposable Robotic System for Endovascular Procedures
HINGHAM, Mass., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ: MBOT) today announced the revealing of LIBERTYTM, the world’s first fully disposable robotic system for use in neurova...
HINGHAM, Mass., Oct. 30, 2019 (GLOBE NEWSWIRE) -- In an expansion of its significant global patent estate, Microbot Medical Inc. (Nasdaq: MBOT) announced that the U.S. Patent and Trademark Office (USP...
Maintains Regulatory Pre-Submission Timeline of the Self-Cleaning Shunt (SCS TM )
HINGHAM, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- At the upcoming Rodman & Renshaw Global Investment Conference, Harel Gadot, CEO, President and Chairman of Microbot Medical Inc. (Nasdaq: MBOT), will...
About MBOT
Microbot Medical Inc., a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable self-propelled locomotive device to treat capabilities within tubular lumens, such as the blood vessels, respiratory, and the urinary and GI tracts; a combination of a... [Read more...]
| Industry Medical Instruments & Supplies | Founded 2010 |
| CEO Harel Gadot | Employees 14 |
| Stock Exchange NASDAQ | Ticker Symbol MBOT |
Analyst Forecasts
According to one analyst, the rating for MBOT stock is "Buy" and the 12-month stock price forecast is 20.00.